Alnylam Releases Phase III ILLUMINATE-A Trial Results Testing Lumasiran for PH1
Alnylam's Lumasiran is an experimental RNA interference therapy that targets hydroxy acid oxidase 1 (HAO1) responsible for the production of the glycolate oxidase (GO), thus blocking the production of oxalate.
AstraZeneca's Blood Cancer Drug Calquence Might be the New Weapon to Fight COVID-19
The preliminary research showed that the drug - Calquence, a Bruton Tyrosine Kinase (BTK) Inhibitor - was able to improve oxygenation of the patients with ARDS due to coronavirus.
Astellas Presents Phase III DOLOMITES Trial Results, Shows Non-inferiority of its Roxadustat to Amgen's Aranesp
The results demonstrated Roxadustat was belt meet the primary endpoint and was proved non-inferior to Aranesp in hemoglobin levels during the first 24 weeks of treatment.
Evotec Partners with Advanced BioScience Laboratories, Plans to Design Bradly Neutralising Antibody Against HIV
Under the terms of the agreement, Just - Evotec Biologics will be responsible for developing a highly efficient manufacturing process required for the production of Phase I cGMP clinical supply of a broadly neutralizing antibody ("bnAb") against HIV.
For more detailed information visit:
https://www.delveinsight.com/blog/recent-pharma-happenings-for-alnylam-astrazeneca-evotec-astellas/